Deubiquitinases in hematological malignancies

Deubiquitinases (DUBs) are enzymes that control the stability, interactions or localization of most cellular proteins by removing their ubiquitin modification. In recent years, some DUBs, such as USP7, USP9X and USP10, have been identified as promising therapeutic targets in hematological malignanci...

Full description

Saved in:
Bibliographic Details
Published in:Biomarker research 2021-08, Vol.9 (1), p.66-23, Article 66
Main Authors: Lei, Hu, Wang, Jiaqi, Hu, Jiacheng, Zhu, Qian, Wu, Yingli
Format: Article
Language:English
Subjects:
Analysis
Apoptosis
Bone marrow
Carfilzomib
Cell cycle
Cell growth
Chemotherapy
Clinical trials
Deubiquitinases
Disease
DNA damage
Drug resistance
Gene amplification
Health aspects
Hematological malignancies
Hematology
Kinases
Leukemia
Localization
Lymphoma
Lymphomas
Multiple myeloma
Pathogenesis
Proteins
Remission (Medicine)
Review
Stem cells
Therapeutic applications
Therapeutic targets
Tumor necrosis factor-TNF
Tumor suppressor genes
Tumorigenesis
Ubiquitin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Deubiquitinases (DUBs) are enzymes that control the stability, interactions or localization of most cellular proteins by removing their ubiquitin modification. In recent years, some DUBs, such as USP7, USP9X and USP10, have been identified as promising therapeutic targets in hematological malignancies. Importantly, some potent inhibitors targeting the oncogenic DUBs have been developed, showing promising inhibitory efficacy in preclinical models, and some have even undergone clinical trials. Different DUBs perform distinct function in diverse hematological malignancies, such as oncogenic, tumor suppressor or context-dependent effects. Therefore, exploring the biological roles of DUBs and their downstream effectors will provide new insights and therapeutic targets for the occurrence and development of hematological malignancies. We summarize the DUBs involved in different categories of hematological malignancies including leukemia, multiple myeloma and lymphoma. We also present the recent development of DUB inhibitors and their applications in hematological malignancies. Together, we demonstrate DUBs as potential therapeutic drug targets in hematological malignancies.
ISSN:2050-7771
2050-7771
DOI:10.1186/s40364-021-00320-w